Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: mattstat who wrote (9038)	9/28/2017 10:16:47 AM
From: drkaz	Read Replies (1) \| Respond to of 12871

I believe you are far-fetched here.

To: mattstat who wrote (9038)	9/28/2017 12:58:09 PM
From: HardToFind	Read Replies (1) \| Respond to of 12871

No, my sense is they know HerpeCide would no longer play well in the market with all the vaccines on the horizon. They can't compete with this. They know it. So they need another winner out of the gate. Especially now that they need money. So in order to impress their PIPE financiers, they may be going back to FluCide (maybe). But I think they believe they have no choice now and have to put all in their eggs in a basket once again. While I agree that the delays have been frustrating, I think they're going to be able to use the same drug formulation for shingles, cold sores and genital herpes. This is the one. FluCide is not the horse to ride for their first shot a drug approval for multiple reasons: The IV formulation requires a 20-50x more nano-material than herpes will for each treatment, and the oral FluCide formulation will require three times more nano-material than the IV formulation. The IV can only be given out in a hospital setting. Old people are most at risk of death, so during the trials you run the risk of people dying for unrelated issues. Tox testing requirements for a systemic drug would create a long delay.